EUVIMEDEUVIMED entdecken
FallberichtOpen Access

Exploring the role of combined external beam radiotherapy and targeted radioligand therapy with [ 177 Lu]Lu-PSMA-617 for prostate cancer - from bench to bedside

Daria Arbuznikova, Aikaterini Klotsotyra, Lisa Uhlmann, Lisa-Charlotte Domogalla, Nils Steinacker, Michael Mix, Gabriele Niedermann, Simon K B Spohn, Martin T Freitag, Anca L Grosu, Philipp T Meyer, Christian Gratzke und 3 weitere

Theranostics · 2024

DOI: 10.7150/thno.93249 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Theranostics, 2024. Verfasst von Daria Arbuznikova und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Lutetium, Heterocyclic Compounds, 1-Ring, Dipeptides. Die Arbeit wurde bisher 27-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsLutetiumHeterocyclic Compounds, 1-RingDipeptidesRadiopharmaceuticalsRadioisotopesProstate-Specific AntigenAnimalsMaleHumansCell Line, TumorMiceMice, Inbred BALB CMice, NudeGlutamate Carboxypeptidase IIXenograft Model Antitumor AssaysAntigens, Surface

Stichwörter der Autor:innen

combination therapyexternal beam radiotherapyprostate cancerprostate-specific membrane antigentargeted radioligand therapy

Substanzen

LutetiumHeterocyclic Compounds, 1-RingDipeptidesPSMA-617RadiopharmaceuticalsRadioisotopesLutetium-177Glutamate Carboxypeptidase IIFOLH1 protein, humanAntigens, Surface

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Division of Radiopharmaceutical Development, German Cancer Consortium (DKTK), partner site Freiburg, Freiburg, Germany and German Cancer Research Center, Heidelberg, Germany.
  • Department of Radiation Oncology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • German Cancer Consortium (DKTK), partner site Freiburg, a partnership between the German Cancer Research Center and Medical Center - University of Freiburg, Freiburg, Germany.
  • Berta-Ottenstein-Program, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Department of Urology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.

Zitieren

APA

Arbuznikova, D., Klotsotyra, A., Uhlmann, L., Domogalla, L. C., Steinacker, N., Mix, M., Niedermann, G., Spohn, S. K. B., Freitag, M. T., Grosu, A. L., Meyer, P. T., Gratzke, C., Eder, M., Zamboglou, C., & Eder, A. C. (2024). Exploring the role of combined external beam radiotherapy and targeted radioligand therapy with [ 177 Lu]Lu-PSMA-617 for prostate cancer - from bench to bedside. Theranostics. https://doi.org/10.7150/thno.93249

Vancouver

Arbuznikova D, Klotsotyra A, Uhlmann L, Domogalla LC, Steinacker N, Mix M, et al. Exploring the role of combined external beam radiotherapy and targeted radioligand therapy with [ 177 Lu]Lu-PSMA-617 for prostate cancer - from bench to bedside. Theranostics. 2024. doi:10.7150/thno.93249

BibTeX
@article{Arbuznikova2024,
  author = {Arbuznikova, Daria and Klotsotyra, Aikaterini and Uhlmann, Lisa and Domogalla, Lisa-Charlotte and Steinacker, Nils and Mix, Michael and Niedermann, Gabriele and Spohn, Simon K B and Freitag, Martin T and Grosu, Anca L and Meyer, Philipp T and Gratzke, Christian and Eder, Matthias and Zamboglou, Constantinos and Eder, Ann-Christin},
  title = {Exploring the role of combined external beam radiotherapy and targeted radioligand therapy with [ 177 Lu]Lu-PSMA-617 for prostate cancer - from bench to bedside},
  journal = {Theranostics},
  year = {2024},
  doi = {10.7150/thno.93249}
}
Kostenlos starten →